Tropomyosin receptor kinase inhibitors: a patent update 2009 – 2013

Bibliography

• Cohen S, Levi-Montalcini R, Hamburger V. A nerve growth-stimulating factor isolated from sarcomas 37 and 180. Proc Natl Acad Sci USA 1954;40:1014-18
   PubMed Web of Science ®Google Scholar
• Klein R, Nanduri V, Jing SA, et al. Cloning and expression of a novel neurotrophin, NT-7, from carp. Cell 1991;66:395-403
   PubMed Web of Science ®Google Scholar
• Gotz R, Koster R, Winkler C, Raulf F. Neurotrophin-6 is a new member of the nerve growth factor family. Nature 1994;372:266-9
   PubMed Web of Science ®Google Scholar
• Ip NY, Ibanez CF, Nye SH, McClain J. Mammalian neurotrophin-4: structure, chromosomal localisation, tissue distribution and receptor specificity. Proc Natl Acad Sci USA 1992;89:3060-4
   PubMed Web of Science ®Google Scholar
• Lamballe F, Klein R, Barbacid M. TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 1991;66:967-79
   PubMed Web of Science ®Google Scholar
• Gschwind A, Fischer OM, Ullrich A. The discovery of receptor kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70
   PubMed Web of Science ®Google Scholar
• Thiele CJ, Li Z, McKee AE. On Trk-the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res 2009;15:5962-7
   PubMed Web of Science ®Google Scholar
• Papatsoris AG, Liolitsa D, Deliveliotis C. Manipulation of the nerve growth factor network in prostate cancer. Expert Opin Investig Drugs 2007;16:303-9
   PubMed Web of Science ®Google Scholar
• Weeraratna AT, Arnold JT, George DJ. Rational basis for Trk inhibition therapy for prostate cancer. Prostate 2000;45:140-8
   PubMed Web of Science ®Google Scholar
• Hondermarck H. Neurotrophins and their receptors in breast cancer. Cytokine Growth Factor Rev 2012;23:357-65
   PubMedGoogle Scholar
• Sclabas GM, Fujioka S, Schmidt C. Overexpression of tropomyosin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 2005;11:440-9
   PubMed Web of Science ®Google Scholar
• Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 1998;153:1451-8
   PubMed Web of Science ®Google Scholar
• Euhus DM, Timmons CF, Tomlinson GE. ETV6-NTRK3-Trk-ing the primary event in human secretory breast cancer. Cancer Cell 2002;2:347-8
   PubMed Web of Science ®Google Scholar
• Pierotti MA, Greco A. Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Lett 2006;232:90-8
   PubMed Web of Science ®Google Scholar
• Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol 2010;321:44-9
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013;19:1469-72
   PubMed Web of Science ®Google Scholar
• Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 2013;73:2031-51
   PubMed Web of Science ®Google Scholar
• Indo Y, Tsuruta M, Hayashida Y. Mutations in the TrkA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet 1996;13:485-8
   PubMed Web of Science ®Google Scholar
• Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from Osteoarthritis of the knee. N Engl J Med 2010;363:1521-31
   PubMed Web of Science ®Google Scholar
• Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces Osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 2013;65:1795-803
   PubMed Web of Science ®Google Scholar
• Ghilardi JR, Freeman KT, Jimenez-Andrade JM, et al. Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain. Mol Pain 2010;6:87-100
   PubMed Web of Science ®Google Scholar
• Skerratt S. The discovery and optimisation of a series of potent, selective and CNS restricted pan-Trk ligands for pain. 2013
   Google Scholar
• Andrews SW. Allosteric Small Molecule Inhibitors of the NGF/TrkA Pathway. A New Approach to Treating Inflammatory Pain. Array Website,2012. Available from: http://www.arraybiopharma.com/_documents/Publication/PubAttachment587.pdf [Last accessed 22 January 2014]
   Google Scholar
• Kim JS, Kang JY, Ha JH, et al. Expression of nerve growth factor and matrix metallopeptidase-9/tissue inhibitor of metalloproteinase-1 in asthmatic patients. J Asthma 2013;50:712-17
   PubMed Web of Science ®Google Scholar
• Yang YG, Tian WM, Zhang H. Nerve growth factor exacerbates allergic lung inflammation and airway remodeling in a rat model of chronic asthma. Exp Ther Med 2013;6:1251-8
   PubMed Web of Science ®Google Scholar
• Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327. PR Newswire. 2013. Available from: http://www.prnewswire.com/news-releases/creabilis-announces-headline-results-of-its-phase-2b-trial-of-topical-trka-kinase-inhibitor-ct327-206885021.html [Last Accessed 22 January 2014]
   Google Scholar
• Weinkauf C, Pereiraperrin M. Trypanosoma cruzi promotes neuronal and glial cell survival through the neurotrophic receptor TrkC. Infect Immun 2009;77:1368-75
   PubMedGoogle Scholar
• Weinkauf C, Salvador R, Pereiraperrin M. Neurotrophin receptor TrkC is an entry receptor for Trypanosoma cruzi in neural, glial, and epithelial cells. Infect Immun 2011;79:4081-7
   PubMedGoogle Scholar
• Albaugh P, Fan Y, Mi Y, Sun F. Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Med Chem Lett 2012;3:140-5
   PubMed Web of Science ®Google Scholar
• Pargellis C, Tong L, Churchill L. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;9:268-72
   PubMedGoogle Scholar
• Wang T, Lamb ML, Block MH, et al. Discovery of Disubstituted Imidazo[4,5-b]pyridines and purines as potent TrkA inhibitors. ACS Med Chem Lett 2012;3:705-9
   PubMed Web of Science ®Google Scholar
• Wang T, Lamb ML, Scott DA, et al. Identification of 4-Aminopyrazolylpyrimidines as potent inhibitors of Trk kinases. J Med Chem 2008;51:4672-84
   PubMed Web of Science ®Google Scholar
• Bertrand T, Kothe M, Liu J. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. J Mol Biol 2012;423:439-53
   PubMed Web of Science ®Google Scholar
• Wang T, Yu D, Lamb ML. Trk kinase inhibitors as new treatments for cancer and pain. Expert Opin Ther Pat 2009;19:305-19
   PubMed Web of Science ®Google Scholar
• Andrews SW, Haas J, Jiang Y, Zhang G. Substituted imidazo[1,2-b]pyridazine compounds as Trk kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2010033941; 2010
   Google Scholar
• Haas J, Andrews SW, Jiang Y, Zhang G. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors and their preparation and use in the treatment of diseases. WO2010048314; 2010
   Google Scholar
• Allen S, Andrews SS, Condroski KR, et al. Preparation of substituted pyrazolo[1,5-a]pyrimidine compounds as selective Trk kinase inhibitors. WO2011006074; 2011
   Google Scholar
• Blaney J, Gibbons PA, Hanan E, et al. Pyrazolopyrimidines as JAK inhibitor compounds and their preparation. WO2010051549; 2010
   Google Scholar
• Andrews SW, Condroski KR, Haas J, et al. Preparation of macrocyclic compounds as trk kinase inhibitors. WO2011146336; 2011
   Google Scholar
• Allen S, Andrews SW, Blake JF, et al. Pyrrolidinylurea and pyrrolidinylthiourea compds. as TrkA kinase inhibitors and their preparation. WO2012158413; 2012
   Google Scholar
• Marx MA, La Greca SD, Chen J, et al. Preparation of pyrrolopyrimidine derivatives useful in cancer treatment. WO2005116035; 2005
   Google Scholar
• Chen P, Zhao Y, Fink BE, Kim S-H. Preparation of 4-aminopyrrolotriazines as tropomyosin related kinase inhibitors for the treatment of proliferative diseases. US7514435B2; 2009
   Google Scholar
• John V, Zhang Q, Bredesen DE. TrkA as a target for inhibiting APP cleavage and/or progression of Alzheimer's disease. WO2013026021; 2013
   Google Scholar
• Galvan V, Gorostiza OF, Banwait S, et al. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci USA 2006;103:7130-5
   PubMed Web of Science ®Google Scholar
• Katz J, Jewell J, Jung J, et al. Preparation of pyrazolopyridines and imidazopyridines as inhibitors of the kinase PDK1 useful for the treatment of myeloproliferative disorders or cancer. WO2010017047; 2010
   Google Scholar
• Green A, Li Y, Stachel S. Preparation of pyridotriazole and benztriazole compds. as TrkA kinase inhibitors. WO2012125667; 2012
   Google Scholar
• Green A, Li Y, Stachel S. TrkA kinase inhibitors, compositions and methods of use. WO2012125668; 2012
   Google Scholar
• Hanney B, Manley P, Rudd MT, et al. Preparation of substituted pyrrolopyrazines and indoles as TrkA kinase inhibitors. WO2013009582; 2013
   Google Scholar
• Stachel SJ, Egbertson M, Brnardic E, et al. Trka kinase inhibitors, compositions and methods thereof. WO2013176970; 2013
   Google Scholar
• Scaburri A, Pacciarini MA, Ciomei M, et al. Use of a kinase inhibitor for the treatment of thymoma. WO2010106028; 2010
   Google Scholar
• Albaugh PA, Choi H-S, Chopiuk G, et al. Preparation of imidazopyridazines and similar compounds as therapeutic kinase inhibitors. WO2009140128; 2009
   Google Scholar
• Warmuth M, Kim S, Gu XJ. Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol 2007;19:55-60
   PubMed Web of Science ®Google Scholar
• Fan Y, Loren J, Molteni V, et al. Preparation of imidazopyridazine derivatives for use as TRK inhibitors. WO2012034091; 2012
   Google Scholar
• Harbeson SL, Tung RD. Deuterium in drug discovery and development. Annu Rep Med Chem 2011;46:403-17
   Google Scholar
• Loren J, Molteni V, Fan Y, et al. Preparation of pyrazolopyrimidine derivatives for use as TRK inhibitors. WO2012034095; 2012
   Google Scholar
• Molteni V, Fan Y, Loren J, et al. Pyrazolopyridine derivatives as TRK kinase inhibitors and their preparation and use for the treatment of TRK kinase-mediated diseases. WO2012116217; 2012
   Google Scholar
• Takeuchi J, Ikura M, Higashino M, et al. Preparation of thiazole-containing urea derivatives as tropomyosin receptor kinase (Trk kinase) inhibitors. WO2013161919; 2013
   Google Scholar
• Andrews MD, Bagal SK, Gibson KR, et al. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases and their preparation and use in the treatment of pain. WO2012137089; 2012
   Google Scholar
• Sasmal PK, Ahmed S, Prabhu G, et al. Preparation of substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors. WO2013088257; 2013
   Google Scholar
• Sasmal PK, Ahmed S, Tehim A, et al. Preparation of substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors. WO2013088256; 2013
   Google Scholar
• Wilcoxen KM. Modulating certain tyrosine kinases. WO2013074518; 2013
   Google Scholar
• Bode CM, Cheng AC, Choquette D, et al. Preparation of azabenzimidazole derivatives and analogs for use as anaplastic lymphoma kinase inhibitors. WO2012018668; 2012
   Google Scholar
• Lewis RT, Bode CM, Choquette DM, Potashman M. The discovery and optimization of a novel class of potent, selective, and orally bioavailable Anaplastic Lymphoma Kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem 2012;55:6523-40
   PubMed Web of Science ®Google Scholar
• Wu JJ-Q, Wang L. Preparation of and therapeutic compositions containing heterocyclic protein receptor tyrosine kinase inhibitors. WO2010077680; 2010
   Google Scholar
• Scott LJ. Tofacitinib: a Review of its Use in Adult Patients with Rheumatoid Arthritis. Drugs 2013;73:857-74
   PubMed Web of Science ®Google Scholar
• Salama AKS, Kim KB. (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother 2013;14:619-27
   PubMed Web of Science ®Google Scholar
• Jang S, Atkins MB. Treatment of BRAF-mutant melanoma: the role of Vemurafenib and other therapies. Clin Pharmacol Ther 2014;95:24-31
   PubMedGoogle Scholar
• Medina T, Amaria M.N, Jimeno A. Dabrafenib in the treatment of advanced melanoma. Drugs Today (Barc) 2013;49:377-85
   PubMedGoogle Scholar
• Narayanan V, Pollyea DA, Gutman JA, Jimeno A. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Drugs Today (Barc) 2013;49:261-9
   PubMedGoogle Scholar
• Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007;18:3-10
   PubMedGoogle Scholar
• Demetri GD, Reicchardt P, Kang YK, Blay JY. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295-302
   PubMed Web of Science ®Google Scholar
• Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 2010;53:1413-37
   PubMed Web of Science ®Google Scholar
• Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76
   PubMed Web of Science ®Google Scholar
• Santos FPS, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131-6
   PubMed Web of Science ®Google Scholar
• Shabbir M SR. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs 2010;19:427-36
   PubMedGoogle Scholar
• Boss DS, Beijnen JH, Schellens JHM. Clinical experience with Aurora kinase inhibitors: a review. Oncologist 2009;14:780-93
   PubMed Web of Science ®Google Scholar
• Logan TF. Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer. Curr Oncol Rep 2013;15:83-90
   PubMed Web of Science ®Google Scholar
• Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918. NIH clinical trial notification. 2010. Available from: http://clinicaltrials.gov/show/NCT00733031 [Last accessed 21 January 2014]
   Google Scholar
• Huang EJ, Reichardt LF. Trk receptors:roles in neuronal signal transduction. Annu Rev Biochem 2003;72:609-42
   PubMed Web of Science ®Google Scholar
• Gibbons DL, Pricl S, Kantarjian H, Cortes J. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer 2012;118:293-9
   PubMed Web of Science ®Google Scholar
• Bikker JA, Brooijmans N, Wissner A, Mansour TS. Kinase domain mutations in cancer: implications for small molecule drug design strategies. J Med Chem 2009;52:1493-509
   PubMed Web of Science ®Google Scholar